Although previous research has demonstrated that prolactin and sex hormones are associated with an increased risk of gynecologic cancers [43,44,45,46], TCAs and SSRIs may exert additional hormonal regulatory mechanisms that could mitigate the pro-tumor influences of prolactin and estrogen, thereby contributing to a net antitumor effect. Here, PRL is linked to female reproductive organ cancer.